SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Valuation in Focus After Landmark FDA Approval for POHERDY Biosimilar

Shanghai Henlius Biotech (SEHK:2696) is in focus after the US FDA approved its Biologics License Application for POHERDY. This approval makes POHERDY the first pertuzumab biosimilar available in the US through a partnership with Organon. See our latest analysis for Shanghai Henlius Biotech. Henlius’s recent FDA approval comes on the heels of a remarkable run. After some profit-taking, the stock’s latest price is HK$65.25, and its year-to-date share price return is an eye-catching 177.66%...
SEHK:6618
SEHK:6618Consumer Retailing

JD Health (SEHK:6618): Valuation in Focus as Strong Results and Partnerships Drive Stock Higher

JD Health International (SEHK:6618) delivered a strong set of third-quarter results, outpacing market forecasts for both revenue and profit. The company also rolled out new collaborations and initiatives that broaden its digital healthcare reach. See our latest analysis for JD Health International. JD Health International’s latest quarterly results have electrified its share price, delivering a 1-month share price return of 14.2% and driving its year-to-date gain to an impressive 162.9%. An...
SEHK:2616
SEHK:2616Biotechs

CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone

CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, CS2009 has cleared an IND milestone in China. See our latest analysis for CStone Pharmaceuticals. CStone’s share price has surged 148% year-to-date and delivered an exceptional 227% total shareholder return over the past year. This performance has been fueled in recent days by promising advances in...
SEHK:2190
SEHK:2190Medical Equipment

Three Asian Growth Stocks With Significant Insider Ownership

As global markets navigate the aftermath of the longest U.S. government shutdown in history and fluctuating economic indicators, Asian markets are experiencing their own set of challenges and opportunities, with Chinese stocks retreating amid concerns over economic momentum and Japan's indices rising on policy expectations. In this environment, identifying growth companies with substantial insider ownership can be particularly appealing to investors seeking alignment between management...
SEHK:1765
SEHK:1765Consumer Services

Asian Penny Stocks Under US$600M Market Cap To Consider

As global markets navigate a complex landscape marked by mixed performances and economic uncertainties, the Asian market remains a focal point for investors seeking growth opportunities. Penny stocks, often seen as relics of earlier market days, continue to offer potential for significant returns, especially when backed by strong financial health and solid fundamentals. In this article, we explore several Asian penny stocks that stand out with robust balance sheets and promising prospects in...
SEHK:6855
SEHK:6855Biotechs

Asian Growth Companies With High Insider Ownership In November 2025

As Asian markets navigate a landscape marked by economic challenges and investor caution, the focus on insider ownership becomes increasingly relevant. In this context, companies with significant insider stakes can offer insights into potential growth opportunities, as they often reflect confidence from those closest to the business.
SEHK:2145
SEHK:2145Personal Products

3 Asian Stocks Estimated To Be Trading Below Their Intrinsic Value By Up To 48.2%

As global markets navigate a complex landscape marked by economic uncertainties and shifting investor sentiment, the Asian stock market presents intriguing opportunities for those seeking value. In this context, identifying stocks trading below their intrinsic value can offer potential for growth, especially as investors look to balance risk with the promise of long-term returns amidst current market conditions.
SEHK:1209
SEHK:1209Real Estate

Does China Resources Mixc Lifestyle (SEHK:1209) Share Sale Reveal a Shift in Capital Allocation Priorities?

Earlier this week, China Resources Land announced it would sell approximately 49.5 million shares of China Resources Mixc Lifestyle Services for about HK$2 billion, reducing its stake from 72.29% to 70.12%. This transaction was executed at nearly a 10 percent discount to the previous closing price and is intended to raise funds for acquiring land reserves and covering development costs. We'll consider how this reduced ownership stake and discounted placement could influence the company's...
SEHK:551
SEHK:551Luxury

What Do Lower Earnings Mean for Yue Yuen (SEHK:551)'s Long-Term Competitive Positioning?

Yue Yuen Industrial (Holdings) reported earnings for the nine months ended September 30, 2025, with sales of US$6.02 billion and net income of US$278.72 million, both reflecting decreases compared to the same period last year. The declines in both sales and profitability suggest that operational challenges or shifting market demand may have impacted the company's core business during this period. We’ll explore how the dip in net income shapes Yue Yuen Industrial’s investment narrative and...
SEHK:1913
SEHK:1913Luxury

Prada (SEHK:1913): Exploring the Brand’s Valuation After a Week of Share Price Volatility

Prada (SEHK:1913) has seen its shares fluctuate this week, prompting investors to take a closer look at what is driving recent price action. The past month has delivered modest gains, raising some interesting valuation questions. See our latest analysis for Prada. Prada’s latest week of trading brought a mix of volatility and modest upward movement, with a 5.8% 7-day share price return standing out within an ongoing period of market recalibration. While momentum has been choppy lately, it’s...
SEHK:2171
SEHK:2171Biotechs

CARsgen Therapeutics (SEHK:2171) Is Up 13.3% After Encouraging CAR-T Cell Therapy Results in Tough Cases

Earlier in November 2025, CARsgen Therapeutics Holdings announced updated clinical data for its allogeneic CAR-T cell therapy candidates, CT0596 and CT1190B, revealing initially favorable safety and efficacy outcomes in heavily pretreated patients with relapsed/refractory multiple myeloma and non-Hodgkin’s lymphoma. An interesting insight is that some patients who had failed multiple previous advanced therapies achieved complete responses, highlighting the potential impact of these...